Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorders diagnosed in children around the world. DMD is often referred to as orphan or rare diseases, as it affects only a small portion of the population, approximately 1 in every 3,500 live male births. However, various treatment approaches are available now-a-days that can inhibit progression of the disease. Amongst, the most attractive are molecular based therapies, such as mutation suppression or exon skipping. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.
The Duchenne Muscular Dystrophy Therapeutics industry can possibly turn into a multi-million dollar industry by the end of 2022, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.
The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51. The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products.
Key Market Drivers:
Growing Prevalence of Duchenne Muscular Dystrophy
Rising Acceptance of Duchenne Muscular Dystrophy Drugs in the Market
Increasing Funding Support & Grants
Catabasis Pharmaceuticals, Inc.
Marathon Pharmaceuticals, LLC
NS Pharma, Inc.
PTC Therapeutics, Inc.
ReveraGen BioPharma, Inc.
Sarepta Therapeutics, Inc.
Summit Therapeutics plc
Taiho Pharmaceutical Co
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Duchenne Muscular Dystrophy (DMD): An Overview
4. Market Dynamics
5. Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022